

**Terence Kelley, M.S. HCA
Program Manager, Alzheimer's Disease Program
(Interim) Policy Lead for the Chronic Disease Control Branch
California Department of Public Health**

Terence Kelley's background is in social and behavioral sciences with a Master's of Science in Health Care Administration and an undergraduate degree in Business Administration and Economics. Terence worked in government administration in health care services and administration, long-term care, pharmacy benefits and public health for 10+ years with experience in research, finance, and health policy analysis. Terence currently serves as the Program Manager for the Alzheimer's Disease Program at California Department of Public Health (CDPH), Chronic Disease Control Branch. In this role, Mr. Kelley provides leadership, organization, planning, strategy, and technical programmatic evaluation of the State Alzheimer's Disease Program. This includes oversight of funding for 10 grants to operate the California Alzheimer's Disease Centers (CADCs) which includes Veteran Administration (VA) hospital systems housed at Tier 1 University medical and research centers. Mr. Kelley collaborates with a team of clinical staff at the CADCs including neurologists, neuropsychiatrists, geriatric nurse practitioners, researchers and social workers among others. In addition, Mr. Kelley provides oversight of seven Alzheimer's disease and related dementias research grants in the areas of biomarkers and early detection, basic science, caregiving, epidemiology and health disparities. Prior to Mr. Kelley's role at CDPH, he supervised and managed a team of research analysts and specialists overseeing \$1.2 billion in annual Medi-Cal fee-for-service (FFS) reimbursement rates for institutional and community-based long-term care facilities.

**Sarah Kremen, MD
Mary S. Easton Center for Alzheimer's Disease Research at UCLA
David Geffen School of Medicine at UCLA**

Dr. Kremen obtained her medical degree at the University of Maryland in Baltimore in 2003. She completed her residency training in neurology at the University of California, Los Angeles (UCLA), and went on to complete a fellowship in behavioral neurology and neuropsychiatry at the Greater Los Angeles VA Medical Center. She joined the Easton Center for Alzheimer's Disease Research at UCLA in 2010 as a clinical and research physician. Dr. Kremen sees patients with memory, language, and other cognitive disorders in the Dementia and Memory Disorders Clinic in the Department of Neurology at UCLA. She is the Director of the Kagan Alzheimer's Disease Treatment Development Program, running industry and government funded clinical trials for investigative treatments for Alzheimer's disease. Dr. Kremen also serves as the Director of the UCLA California Alzheimer's Disease Center (CADC). The mission of the CADC is to provide clinical services, outreach, and education to the greater Los Angeles community. Dr. Kremen has been involved in local and statewide efforts to improve dementia care for patients, their families, and for healthcare providers through in-person and webinar lectures, community and support group educational forums, and as a contributor to the updated 2017 Alzheimer's Clinical Care Guideline for California. She has been an active collaborator with the other nine state CADCs in their current efforts to build an Early Detection and Diagnosis Toolkit, designed to help primary care providers recognize, evaluate, and treat patients with dementia sooner.

California Department of Public Health

Alzheimer's Disease Program

April 19, 2018

Presentation to the California Medical Board

Terence C. Kelley, M.S. HCA
Alzheimer's Disease Program
Chronic Disease Control Branch
California Department of Public Health

Sarah Kremen, MD
Director, UCLA California Alzheimer's Disease Center
Mary S. Easton Center for Alzheimer's Disease
Research at UCLA



California Department of Public Health

Alzheimer's Disease Program

The State of California provides administrative oversight for:

- Ten California Alzheimer's Disease Centers (CADCs)
 - Diagnosis and treatment of patients
 - Education and training of health professionals
 - Evaluation of the ten Alzheimer's Disease Centers
- Alzheimer's Disease Research Tax Check-Off Fund
 - Provision of more than \$24 million in research funds to university researchers, medical centers, health systems, and others.
- Senate Bill 613 (Guideline for Alzheimer's Disease Management) and Senate Bill 833 (Early Diagnosis and Detection Toolkit)



California Department of Public Health

California Alzheimer's Disease Center Locations

- UC Davis – Sacramento
- UC Davis – Walnut Creek
- UC San Francisco
- UC San Francisco – Fresno
- Stanford University

- UC Los Angeles
- University of Southern California (USC)
- USC – Rancho Los Amigos
- UC Irvine
- UC San Diego



California Department of Public Health




California Alzheimer's Disease Center Primary Diagnoses



EDMUND G. BROWN JR.

CADCs Dementia Primary Diagnosis, 2015-2016



Senate Bill 613 (Allen, Chapter 577, Statutes of 2015)

- Required CDPH to convene a multidisciplinary expert workgroup to update the 2008 Guideline for Alzheimer’s Disease Management (Guideline).
- On June 29, 2016: the Program, in partnership with the Alzheimer’s Association, conducted the workgroup comprised of stakeholder experts in Alzheimer’s disease.
- The updated Guideline aligns with:
 - The “Let’s Get Healthy California” Task Force Report (Goal 2. Living Well: Preventing and Managing Chronic Disease)
 - The California State Plan for Alzheimer’s Disease: An Action Plan for 2011-2021
 - The California Wellness Plan, 2014 (Objective 2.4.1S)



California Department of Public Health

Let’s Get Healthy California Task Force Framework

The Triple Aim:
Better Health • Better Care • Lower Costs



California Department of Public Health

Alzheimer's Clinical Care Guideline

- 4th edition of the California Alzheimer's Clinical Care Guideline
- 4 Primary Topic Areas:
 - Assessment
 - Care Plan
 - Education and Support
 - Important Considerations



California Department of Public Health

Alzheimer's Clinical Care Guideline

Assessment

- Understand (or know) the patient, by addressing the patient directly and by monitoring and reassessing changes.

Care Plan

- Include beneficial interventions such as disease management, treat emotional, behavioral and/or mood symptoms, evaluate safety issues, document goals of care, promote healthy living, refer to clinical studies

Education and Support

- Connect with social and community support

Important Considerations

- Include time sensitive issues such as advance planning, capacity evaluation, elder abuse, driving and eligibility for benefits



California Department of Public Health



Alzheimer's Disease and Its Impact



EDMUND G. BROWN JR.

Alzheimer's Disease is the Most Common Form of Dementia and it Disproportionately Impacts Many Californians. Dementia is a general term for memory loss and other impairments serious enough to interfere with daily life. Alzheimer's accounts for 60 to 80 percent of dementia cases and currently impacts an estimated 610,000 Californians, a number projected to grow to 840,000 by 2025. Alzheimer's is the 5th leading cause of death in California and the only condition in the top 10 without a known cause, cure, or prevention.

More women than men have Alzheimer's disease and other dementias such as vascular dementia and dementia with Lewy bodies, among others. Almost two-thirds of Americans with Alzheimer's are women, as are the majority of family caregivers. Older African Americans and Hispanics are more likely than older whites to have Alzheimer's disease and other dementias with African Americans at twice the prevalence rate and Hispanics one and one-half times the rate.

This 2017 Update Reflects New Evidence, Improved Practice and Changes in Law — This is the 4th edition of the California Alzheimer's Clinical Care Guideline, first published in 1998 and revised in 2002 and 2008. The 2017 update specified in statute (SB 613, Chapter 577, 2016) addresses changes in scientific evidence, clinical practice, and state and federal law. Changes include:

NEW GOVERNMENT POLICIES

Medicare Reimbursement — The Centers for Medicare & Medicaid Services (CMS) now reimburses physicians for annual wellness visits every 12 months and includes payment for a Health Risk Assessment, including reimbursement for a cognitive screen. Medicare will pay for cognitive and functional assessments and care planning for patients with Alzheimer's disease and other cognitive impairments.

Adoption of Physician Order for Life Sustaining Treatment (POLST) — The POLST form gives patients more control over their end-of-life care, including medical treatment, extraordinary measures (such as a ventilator or feeding tube) and Cardiopulmonary resuscitation. POLST can prevent unwanted treatments, reduce patient and family suffering, and ensure a patient's wishes are honored.

Social Security Grants Compassionate Allowance Benefit for Early-Onset Individuals — Individuals under age 65 diagnosed with Alzheimer's disease are eligible for the Social Security Administration's compassionate allowance benefit, with minimal objective medical information provided by a physician.

Healthy Brain Initiative — The Centers for Disease Control and Prevention has mapped out a strategy for state and national partnerships through [The Healthy Brain Initiative](#), emphasizing proven public health strategies such as monitoring and evaluation, education and training, policy development, and workforce competencies.

EMERGING PRACTICE TRENDS

Emphasis on Early Detection, Early Diagnosis and Mild Cognitive Impairment — Mild cognitive impairment can cause serious cognitive changes noticed by those individuals who experience changes or by other people, but not severe enough to interfere with daily life or independent function. As with other chronic diseases, public health experts are focusing on possible early interventions to delay the onset and slow the progression of Alzheimer's disease.

New Evidence About Antipsychotic Medications and FDA Black Box Warning Labels — In April 2005, the U.S. Food and Drug Administration (FDA) notified health care professionals that both conventional and atypical antipsychotics are associated with an increased risk of mortality in elderly patients treated for dementia-related psychosis. The FDA notified health care professionals that patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death. Since issuing that notification, the FDA has reviewed additional information that indicates the risk also is associated with conventional antipsychotics.

Gaps in Disclosure and Documentation — Scientists who studied patient surveys and Medicare claims data discovered only 45 percent of those billed for Alzheimer's-related care were told by their doctors of their disease. Overlooking or avoiding diagnosis impedes care and denies access to needed services. In an era of electronic health records, documenting the diagnosis is critically important in order to deliver person-centered care.

Lifestyle Modifications — Some risk factors for dementia, such as age and genetics, cannot be changed, but the brain can be protected by some of the same strategies that guard against cardiovascular risk, including smoking cessation; keeping blood pressure, cholesterol and blood sugar within recommended limits; and maintaining a healthy weight. Regular physical exercise may help lower dementia risk. Diet may impact brain health through its effect on heart health. Evidence suggests heart-healthy eating patterns, such as the Mediterranean diet, which emphasizes eating foods like fish, fruits, vegetables, beans, high-fiber breads and whole grains, nuts, and olive oil may help protect the brain.

2017, rev. 4

California Department of Public Health



Alzheimer's Clinical Care Guideline



EDMUND G. BROWN JR.

ASSESSMENT

Understand (or Know) the Patient

Address the Patient Directly

- Confirm, disclose and document the diagnosis in the patient record.
- Identify the patient's culture, values, primary language, literacy level, and decision-making process.
- Identify the primary caregiver and assess the adequacy of family and other support systems, paying attention to the caregiver's own mental and physical health.

Monitor and Reassess Changes

- Upon sudden changes or significant decline, and at least annually, conduct and document the following:
 - Ability to manage finances and medications, as well as daily functions, including feeding, bathing, dressing, mobility, toileting and continence;
 - Cognitive status, using a valid and reliable instrument, e.g., [MoCA](#), [Montreal Cognitive Assessment](#), [AD8](#) (Asterian Dementia 8) or other tool;

- Comorbid medical conditions, which may present with sudden worsening in cognition and function or changes in behavior, and could complicate management of dementia;
- Emotional, behavioral and/or mood symptoms;
- Medications, both prescription and non-prescription, for appropriate use and contraindications; and
- Adequacy of home environment, including safety, care needs, and [abuse and/or neglect](#).

CARE PLAN

Beneficial Interventions

Disease Management

- Discuss the progression and stages of the disease.
- Evaluate and manage comorbidities in context of dementia and prognosis.
- Consider use of cholinesterase inhibitors, N-Methyl-D-aspartate antagonist, and other medications, if clinically indicated, to slow cognitive decline.
- Promote and refer to social services and community support.

- Consult with or refer to mental health professionals as needed.
- If non-pharmacological approaches prove unsuccessful, THEN use medications targeted to specific emotions, behaviors or moods, if clinically indicated. Note, many medications carry an FDA black box warning and side effects may be serious, significant or fatal.

Document Goals of Care

- Explore preferred intensity of care to include palliative care and end-of-life options such as hospice.
- Provide information and education on advance health care directives, Do Not Resuscitate Orders, [Physicians Orders for Life Sustaining Treatment](#), [Durable Power of Attorney](#) and other documents.

Treat Emotional, Behavioral and/or Mood Symptoms

- First consider non-pharmacologic approaches such as counseling, environmental modification, task simplification, activities, etc.

Evaluate Safety Issues

- Discuss driving, wandering, firearms, fire hazards, etc. Recommend [medical identification](#) for patients who wander.

Promote Healthy Living

- Discuss evidence in support of modifiable risk factors, e.g., regular physical activity and diet/nutrition.

Refer to Clinical Studies

- If interested, advise patient and family of opportunities to participate in [research](#).

EDUCATION AND SUPPORT

Engage with the Community

Connect with Social and Community Support

- Involve the patient directly in care planning, treatment decisions and referrals to community resources.
- As the disease progresses, suggest appropriate home and community-based programs and services.
- Link the patient and caregiver to support organizations for culturally appropriate educational materials and referrals to community and government resources.

For statewide patient and family resources, link to: [California Department of Public Health, Alzheimer's Disease Program](#) (916) 552-9900 [Alzheimer's Disease Program](#) Check for local services in your area.

IMPORTANT CONSIDERATIONS

Time Sensitive Issues

Advance Planning

- Discuss the importance of basic legal and financial planning as part of the care plan and refer for [assistance](#).

Capacity Evaluations

- Assess the patient's decision-making capacity and determine whether a legal surrogate has been or can be identified.
- Consider literacy, language and culture in assessing capacity.

Elder Abuse

- Monitor for evidence of and report all suspicions of abuse (physical, financial, sexual, neglect, isolation, abandonment and/or abduction) to Adult Protective Services, Long-Term Care Ombudsman or the local police department, as required by law.

Driving

- Report the diagnosis of Alzheimer's disease in accordance with California law.

Eligibility for Benefits

- Patients diagnosed with early-onset Alzheimer's disease may be eligible for [Social Security compassionate allowance](#).
- Other benefits may include Department of Veterans Affairs or long-term care insurance coverage under existing policies.

2017, rev. 4

*This guidance may apply to other forms of dementia as well as mild cognitive impairment.

California Department of Public Health

Alzheimer's Clinical Care Guideline

- The ten California Alzheimer's Disease Centers will use this updated guideline for education of primary care physicians and residency training programs.
- It is intended to help primary care physicians and physician extenders offer comprehensive care to patients with Alzheimer's disease.



California Department of Public Health

Alzheimer's Clinical Care Guideline - Dissemination

- Online at the CDPH California Alzheimer's Disease Program website located at:
<https://www.cdph.ca.gov/Programs/CCDPHP/DCDIC/CDCB/Pages/AlzheimersDiseaseResources.aspx> and
<http://www.caalz.org/2017%20Guideline%20FINAL%20RELEASE.pdf>
- The Alzheimer's Association held a meeting in May 2017, disseminated the Guideline to a variety of professional trade associations, and held a press conference with Dr. Charles DeCarli, M.D. Director of the Alzheimer's Disease Center at UC Davis.
- The Medical Board of California published the Guideline in the Summer 2017 Newsletter.



California Department of Public Health

Alzheimer's Clinical Care Guideline – Dissemination (Continued)

- The Alzheimer's Disease Program worked with the Physician Consortium for Performance Improvement (PCPI) to incorporate part of the Guideline into a recommended National Quality Forum clinical quality measure used by the Center for Medicaid and Medicare Services (CMS).



California Department of Public Health

Early Detection and Diagnosis Toolkit

- Senate Bill 833
 - Allocated \$2.5 million from the CA Budget Act of 2016 to each of the ten California Alzheimer's Disease Centers
 - The entire \$2.5 million from SB 833 was evenly distributed to all ten Centers
 - Legislation sponsored by the Alzheimer's Association
 - Funding ends June 30, 2019



California Department of Public Health

Early Detection and Diagnosis Toolkit

- Importance of Early Detection and Diagnosis
- The toolkit is intended for the general clinical practice setting.



Early Detection and Diagnosis Toolkit (Example of how a question is handled)

Questions	Answers typical of normal aging Patient	Answers concerning for cognitive impairment	Answers typical for AD Patient	Answers not typical for AD Patient	Comments
Do you have any problems with your memory or thinking?	<p>Getting into a room and not remembering what I am going for</p> <p>Misplacing my glasses or keys but I find them pretty quickly, and it's occasional</p> <p>Difficulty remember names, words BUT it comes back to them later on</p> <p>Informant says their memory is better than mine</p>	<p>I'm having difficulty recalling recent events (e.g. forgot I paid a bill)</p> <p>Lost my car in the parking lot several times</p> <p>I misplace things often, disrupts my schedule</p> <p>Can't find the words I want to use; Talking less in conversations because I am embarrassed</p>	<p>Person may deny or minimize memory problems</p> <p>I can't remember what I did yesterday</p> <p>I can't remember a conversation or event that others recall</p> <p>Lost my car in the parking lot several times</p> <p>Misplacing things often and it disrupts my schedule</p> <p>Informant reports repetitive questions, story telling</p>	<p>want to say but I just can't say it my family can't understand what I'm saying</p> <p>After surgery, I woke up and couldn't remember who my family was</p> <p>My wife will tell me to answer the phone but I forget what that is</p>	<p>Memory is usually out of proportion to other deficits</p> <p>STM more typically affected than long term</p> <p>Early loss of ability to identify items or use them is not typical</p>



Early Detection and Diagnosis Toolkit Elements

- Principles of the Underlying Toolkit
- Wellness Check/Identification of Significant Cognitive Complaints
- Full Assessment: History and Physical Exam



California Department of Public Health

Early Detection and Diagnosis Toolkit Elements (Continued)

- The toolkit will contain the following elements:
 - Lab and Imaging Assessment
 - Counseling
 - Billing Guidance



California Department of Public Health

Toolkit Innovation Pilot

Geriatric Depression and Dementia Scale

- Stanford University - California Alzheimer's Disease Center has developed the Geriatric Depression and Dementia Scale mobile application.
- The Geriatric Depression and Dementia Scale mobile app is now publicly available for Android and iOS devices.
- Android:
<https://play.google.com/store/apps/details?id=com.stanfordva.gdds>
- iOS:
<https://itunes.apple.com/us/app/id1363062468>



California Department of Public Health



Questions?

Terence Kelley, M.S. HCA, Program Manager
 Alzheimer's Disease Program
 California Department of Public Health
 (916) 552-9952
terence.kelley@cdph.ca.gov

Sarah Kremen, MD, UCLA CADC Director
 Mary S. Easton Center for Alzheimer's Disease Research at University of California, Los Angeles
 710 Westwood Plaza, RNRC C-241
 Los Angeles, CA 90095
 310-794-6039
SKremen@mednet.ucla.edu

Website: [Alzheimer's Disease Program](https://www.cdph.ca.gov/Programs/CCDPPH/DCCID/CDCB/Pages/AlzheimersDiseaseProgram.aspx)

<https://www.cdph.ca.gov/Programs/CCDPPH/DCCID/CDCB/Pages/AlzheimersDiseaseProgram.aspx>